Home›Bexagliflozin

Bexagliflozin

Also known as: Brenzavvy

Sodium-Glucose Cotransporter 2 InhibitorSodium-Glucose Transporter 2 Inhibitors

Route: Oral

3 interactions on record

Bexagliflozin has 3 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Insulin Human, Lithium, Ugt Enzyme Inducers. Patients taking Bexagliflozin should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 1
Moderate: 2

Major (1)

Bexagliflozin + Insulin Human— Concomitant use increases risk of hypoglycemia. A lower dose of insulin may be required when used in combination with be…

Moderate (2)

Bexagliflozin + Lithium— Bexagliflozin may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently upon initia…
Bexagliflozin + Ugt Enzyme Inducers— UGT enzyme inducers may significantly reduce bexagliflozin exposure and lead to decreased efficacy. Consider adding anot…

Bexagliflozin + Insulin Human⚠️Major

Concomitant use increases risk of hypoglycemia. A lower dose of insulin may be required when used in combination with bexagliflozin.

Bexagliflozin + Lithium🟡Moderate

Bexagliflozin may decrease serum lithium concentrations. Monitor serum lithium concentration more frequently upon initiation and discontinuation.

Bexagliflozin + Ugt Enzyme Inducers🟡Moderate

UGT enzyme inducers may significantly reduce bexagliflozin exposure and lead to decreased efficacy. Consider adding another antihyperglycemic agent for additional glycemic control.

Contraindications

4 CONTRAINDICATIONS BRENZAVVY is contraindicated in patients: With hypersensitivity to bexagliflozin or any excipient in BRENZAVVY. Anaphylaxis and angioedema have been reported with sodium-glucose co-transporter 2 (SGLT2) inhibitors. • Hypersensitivity to bexagliflozin or any excipient in BRENZAVVY

Pregnancy & Breastfeeding

8.1 Pregnancy Risk Summary Based on animal data showing adverse renal effects, BRENZAVVY is not recommended during the second and third trimesters of pregnancy. The available data on use of BRENZAVVY during pregnancy are insufficient to determine a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations ) . In animal studies, adverse renal pelvic and tubule dilatations that were not fully reversible were observed in rats when bexagliflozin was administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy at exposures 11 times the 20 mg clinical dose (see Data ) . The estimated background risk of major birth defects is 6% to 10% in women with pre-gestational diabetes with a peri-conceptional HbA1c > 7% and has been reported to be as high as 20% to 25% in women with a peri-conceptional HbA1c > 10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Hypoglycemia and hyperglycemia occur more frequently during pregnancy in patients with pre-gestational diabetes. Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, preeclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity. Data Animal Data Bexagliflozin administered to juvenile rats at 0.3, 3 or 30 mg/kg/day by oral gavage from postnatal days 21 to 90 caused a dose dependent increase in the incidence and severity of renal

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.